Agents and Actions

, Volume 38, Supplement 1, pp 126–134 | Cite as

The use of angiostatic steroids to inhibit cartilage destruction in anin vivo model of granuloma-mediated cartilage degradation

  • P. R. Colville-Nash
  • M. El-Ghazaly
  • D. A. Willoughby
Bone and Cartilage
Received:
Accepted:

Abstract

Angiogenesis is an important component of the development of chronic inflammatory diseases such as rheumatoid arthritis. It is known that clinically used anti-rheumatic drugs exert, in part, effects on the angiogenic response. Little work, however, has investigated the potential of experimental angiostatic therapies in chronic inflammatory disease models. The effect of one such angiostatic treatment, cortisone combined with heparin, was tested in anin vivo model of granuloma-mediated cartilage degradation. Angiostatic treatment significantly retarded the growth of granulomatous tissue, mononuclear cell influx into the granuloma, and the degradation of juxtaposed cartilage. This correlated with a decrease in the vascularity of the granulomatous tissue. Modulation of this component of pathogenesis of “angiogenesis-dependent disease” may be useful as a new therapeutic approach.

Keywords

Rheumatoid Arthritis Arthritis Steroid Heparin Mononuclear Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    H. G. Fassbender and A. Simmling-Annefield,The potential aggressiveness of synovial tissue in rheumatoid arthritis. J. Pathol.139, 399–406 (1983).PubMedGoogle Scholar
  2. [2]
    J. Folkman,How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes Memorial Award Lecture. Cancer Res.46, 467–473 (1986).PubMedGoogle Scholar
  3. [3]
    P. R. Colville-Nash and D. L. Scott,Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications. Ann. Rheum. Dis.51 (7), 919–925 (1992).PubMedGoogle Scholar
  4. [4]
    M. Takigawa, Y. Nishida, F. Suzuki, J. Kishi, K. Yamashita and T. Hayakawa,Induction of angiogenesis in chick yolksac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem. Biophys. Res. Commun.171, 1264–1271 (1990).PubMedGoogle Scholar
  5. [5]
    D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem and J. Folkman,Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature348, 555–557 (1990).PubMedGoogle Scholar
  6. [6]
    R. Crum, S. Szabo and J. Folkman,A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science230, 1375–1378 (1985).PubMedGoogle Scholar
  7. [7]
    J. Folkman, R. Langer, R. J. Linhardt, C. Haudenschild and S. Taylor,Angiogenesis inhibition and tumour regression caused by heparin or a heparin fragment in the presence of cortisone. Science221, 719–725 (1983).PubMedGoogle Scholar
  8. [8]
    D. J. Peacock, M. L. Banquerigo and E. Brahn,Angiogenesis inhibition suppresses collagen arthritis. InProceedings of the 55th Annual Meeting of the American College of Rheumatology. Arth. Rheum,34 (9), Suppl, Abstract 74, S45, (1991).Google Scholar
  9. [9]
    F. B. De Brito, A. R. Moore, M. J. G. Holmes and D. A. Willoughby,Cartilage damage by a granulomatous reaction in a murine species. Br. J. Exp. Path.68, 675–686 (1987).Google Scholar
  10. [10]
    F. B. De Brito, M. J. G. Holmes, S. L. Carney and D. A. Willoughby,Drug effects on a novel model of connective tissue breakdown. Agents and Actions21, 287–289 (1987).PubMedGoogle Scholar
  11. [11]
    K. M. K. Bottomley, R. J. Griffiths, T. J. Rising and A. Steward,A modified rat air pouch model for evaluating the effects of compounds on granuloma-induced cartilage degradation. Br. J. Pharmacol.93, 627–635 (1988).PubMedGoogle Scholar
  12. [12]
    J. F. Woessner,The determination of hydroxyproline in tissue and protein samples containing small proportions of imino acids, Arch. Biochem. Biophys.93, 440–447 (1961).PubMedGoogle Scholar
  13. [13]
    P. J. Bailey, A. Sturm and B. Lopez-Ramos,A biochemical study of the cotton pellet granuloma in the rat: Effects of dexamethasone and indomethacin. Biochem. Pharmacol.31, 1213–1218 (1982).PubMedGoogle Scholar
  14. [14]
    J. W. Woollen, R. Heyworth and P. G. Walker,Studies on glucosaminidase. Biochem. J.78, 111–116 (1961).PubMedGoogle Scholar
  15. [15]
    M. Kimura, K. Amemiya, T. Yamada and J. Suzuki,Quantitative method for measuring adjuvant-induced granuloma angiogenesis in insulin treated diabetic mice. J. Pharmacobio. Dyn.9, 442–446 (1986).PubMedGoogle Scholar
  16. [16]
    A. R. Moore, T. H. P. Hanahoe, F. M. Desa, D. W. Howat, C. L. Chander and D. A. Willoughby,A procedure for assaying the component parts of rat femoral head cartilage and it's application to an in vivo model of cartilage breakdown. Int. J. Immunopathol. Pharmacol.1, 5–10 (1988).Google Scholar
  17. [17]
    R. W. Farndale, C. A. Sayer and A. J. Barrett,A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage culture. Connect. Tissue Res.9, 247–251 (1982).PubMedGoogle Scholar
  18. [18]
    F. P. Altman,Quantitative dehydrogenase histochemistry with special reference to the pentose shunt dehydrogenases. Prog. Histochem. Cytochem.4, 225 (1972).Google Scholar
  19. [19]
    B. Henderson,Quantitative cytochemical measurement of glyceraldehyde-3-phosphate dehydrogenase activity. Histochemistry48, 191–204 (1976).PubMedGoogle Scholar
  20. [20]
    J. Chayen, L. Bitensky and R. G. Butcher,Lactate Dehydrogenase. InPractical Histochemistry, pp. 197–199. Wiley, London, 1973.Google Scholar
  21. [21]
    T. A. Springer,Adhesion receptors of the immune system. Nature346, 425–431 (1990).PubMedGoogle Scholar
  22. [22]
    M. R. Windt and L. J. Rosenwasser,Human vascular endothelial cells produce interleukin-1. Lymphokine Res.3, 281a (1984).Google Scholar
  23. [23]
    F. R. Jirik, T. J. Podor, T. Hirano, T. Kishimoto, D. J. Loskutoff, D. A. Carson and M. Lotz,Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J. Immunol.1, 144–147 (1989).Google Scholar
  24. [24]
    A. Mantovani and E. Dejana,Cytokines as communication signals between leukocytes and endothelial cells. Immunol. Today10, 370–375 (1989).PubMedGoogle Scholar
  25. [25]
    J. S. Pober and M. Gimbrone,Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: Demonstration by monoclonal antibody binding and immunoprecipitation. Proc. Nat. Acad. Sci.79, 6641–6645 (1982).PubMedGoogle Scholar
  26. [26]
    P. E. Dicorleto and D. F. Bowen-Pope,Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc. Natl. Acad. Sci.80, 1919–1923 (1983).PubMedGoogle Scholar
  27. [27]
    R. G. Gryglewski, R. M. Botting and J. R. Vane,Mediators produced by the endothelial cell. Hypertension12, 530–548 (1988).PubMedGoogle Scholar
  28. [28]
    E. A. Jaffe,Endothelial cells. InInflammation: Basic Principles and Clinical Correlates. (Eds. J. I. Gallin, I. M. Goldstein and R. Snyderman) pp. 559–576, Raven Press, New York 1988.Google Scholar
  29. [29]
    E-D. Jarasch, G. Bruder and H. W. Heid,Significance of xanthine oxidase in capillary endothelial cells. Acta Scand. Physiol.548 (suppl), 39–46 (1986).Google Scholar
  30. [30]
    D. A. Willoughby, M. P. S. Seed, A. R. Moore, P. R. Colville-Nash and C. L. Chander,New areas for therapeutic intervention in the treatment of rheumatic disease. Therapie46, 461–467 (1991).PubMedGoogle Scholar
  31. [31]
    C. R. Stevens, D. R. Blake, P. Merry, P. A. Revell and J. R. Levick,A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arth. Rheum.34, 1508–1513 (1991).Google Scholar
  32. [32]
    M. Rooney, D. Condell, W. Quinlan, L. Daly, A. Whelan, C. Feighery and B. Bresnihan,Analysis of the histologic variation in rheumatoid arthritis. Arth. Rheum.31, 956–963 (1988).Google Scholar
  33. [33]
    J. Folkman and D. E. Ingber,Angiostatic steroids. Method of discovery and mechanism of action. Ann. Surg.206, 374–383 (1987).PubMedGoogle Scholar
  34. [34]
    D. E. Ingber, J. A. Madri and J. Folkman,A possible mechanism for inhibition of angiogenesis by angiostatic steroids: Induction of capillary basement membrane dissolution. Endocrinology119(4), 1768–1775 (1986).PubMedGoogle Scholar
  35. [35]
    N. G. Tanaka, N. Sakamoto, A. Tohgo, Y. Nishiyama and H. Ogawa,Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition. Exp. Pathol.30, 143–150 (1986).PubMedGoogle Scholar
  36. [36]
    D. W. Beck, J. J. Olson and R. J. Linhardt,Effect of heparin, heparin fragments, and corticosteroids on cerebral endothelial cell growth in vitro and in vivo. J. Neuropathol. Exp. Neurol.45, 503–512 (1986).PubMedGoogle Scholar
  37. [37]
    R. Cariou, J. L. Harousseau and G. Tobelem,Inhibition of human endothelial cell proliferation by heparin and steroids. Cell. Biol. Int. Rep.12, 1037–1047 (1988).PubMedGoogle Scholar
  38. [38]
    C. L. Stokes, P. B. Weisz, S. K. Williams and D. A. Lauffenburger,Inhibition of microvascular endothelial cell migration by beta-cyclodextrin tetradecasulfate and hydrocortisone. Microvasc. Res.40, 279–284 (1990).PubMedGoogle Scholar
  39. [39]
    I. Harada, T. Kikuchi, Y. Shimomura, M. Yamamoto, H. Ohno and N. Sato,The mode of action of anti-angiogenic steroid and heparin. InAngiogenesis. (Eds. R. Steiner, P. B. Weisz and R. Langer), pp. 445–448, Birkhauser, Basel 1992.Google Scholar
  40. [40]
    C. L. Chander, P. R. Colville-nash, A. R. Moore, D. W. Howat, F. M. Desa and D. A. Wiloughby,The effects of heparin and cortisone on an experimental model of pannus. Int. J. Tissue React.11, 113–116 (1989).PubMedGoogle Scholar
  41. [41]
    N. E. Robertson, C. M. Discafani, E. C. Downs, J. A. Hailey, O. Sarre, R. L. J. Runkle, T. L. Popper and M. L. Plunkett,A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis. Cancer Res.51, 1339–1344 (1991).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1993

Authors and Affiliations

  • P. R. Colville-Nash
    • 1
  • M. El-Ghazaly
    • 1
  • D. A. Willoughby
    • 1
  1. 1.Department of Experimental PathologyThe Medical College of St. Bartholomew's HospitalLondonUK

Personalised recommendations